These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32204943)

  • 41. Immunogenicity and safety of a tetravalent dengue vaccine and a bivalent HPV vaccine given concomitantly or sequentially in girls aged 9 to 14 years in Mexico.
    Arredondo JL; Villagomez Martinez SM; Concepcion Morales M; Meyer S; Toh ML; Zocchetti C; Vigne C; Mascareñas C
    Vaccine; 2021 Jun; 39(25):3388-3396. PubMed ID: 33992441
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study.
    Hss AS; Koh MT; Tan KK; Chan LG; Zhou L; Bouckenooghe A; Crevat D; Hutagalung Y
    Vaccine; 2013 Dec; 31(49):5814-21. PubMed ID: 24135573
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.
    Capeding MR; Tran NH; Hadinegoro SR; Ismail HI; Chotpitayasunondh T; Chua MN; Luong CQ; Rusmil K; Wirawan DN; Nallusamy R; Pitisuttithum P; Thisyakorn U; Yoon IK; van der Vliet D; Langevin E; Laot T; Hutagalung Y; Frago C; Boaz M; Wartel TA; Tornieporth NG; Saville M; Bouckenooghe A;
    Lancet; 2014 Oct; 384(9951):1358-65. PubMed ID: 25018116
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low antibody titers 5 years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naïve vaccinees.
    Velumani S; Toh YX; Balasingam S; Archuleta S; Leo YS; Gan VC; Thein TL; Wilder-Smith A; Fink K
    Hum Vaccin Immunother; 2016 May; 12(5):1265-73. PubMed ID: 26889737
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Analysis of the evidence on the efficacy and safety of CYD-TDV dengue vaccine and its potential licensing and implementation through Mexico's Universal Vaccination Program].
    Hernández-Ávila M; Lazcano-Ponce E; Hernández-Ávila JE; Alpuche-Aranda CM; Rodríguez-López MH; García-García L; Madrid-Marina V; López Gatell-Ramírez H; Lanz-Mendoza H; Martínez-Barnetche J; Díaz-Ortega JL; Ángeles-Llerenas A; Barrientos-Gutiérrez T; Bautista-Arredondo S; Santos-Preciado JI
    Salud Publica Mex; 2016; 58(1):71-83. PubMed ID: 26879510
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to dengue virus.
    Nascimento EJM; George JK; Velasco M; Bonaparte MI; Zheng L; DiazGranados CA; Marques ETA; Huleatt JW
    J Virol Methods; 2018 Jul; 257():48-57. PubMed ID: 29567514
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dengue Vaccine Booster in Healthy Adolescents and Adults in Latin America: Evaluation 4-5 Years After a Primary 3-Dose Schedule.
    Coronel D; García-Rivera EJ; Rivera M; Arredondo-García JL; Dietze R; Perroud AP; Cortés M; Bonaparte M; Zhao J; Tila M; Jackson N; Zambrano B; Noriega F
    Pediatr Infect Dis J; 2019 May; 38(5):e90-e95. PubMed ID: 30986790
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward.
    Guy B; Briand O; Lang J; Saville M; Jackson N
    Vaccine; 2015 Dec; 33(50):7100-11. PubMed ID: 26475445
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity and Safety of a Booster Injection of DTap-IPV//Hib (Pentaxim) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers 15-18 Months of Age in Mexico: A Randomized Trial.
    Melo FIR; Morales JJR; De Los Santos AHM; Rivas E; Vigne C; Noriega F
    Pediatr Infect Dis J; 2017 Jun; 36(6):602-608. PubMed ID: 28067718
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning.
    Dorigatti I; Donnelly CA; Laydon DJ; Small R; Jackson N; Coudeville L; Ferguson NM
    Nat Commun; 2018 Sep; 9(1):3644. PubMed ID: 30194294
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore.
    Leo YS; Wilder-Smith A; Archuleta S; Shek LP; Chong CY; Leong HN; Low CY; Oh ML; Bouckenooghe A; Wartel TA; Crevat D
    Hum Vaccin Immunother; 2012 Sep; 8(9):1259-71. PubMed ID: 22894958
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
    Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian survival analysis of individual-level phase III data.
    Laydon DJ; Dorigatti I; Hinsley WR; Nedjati-Gilani G; Coudeville L; Ferguson NM
    Elife; 2021 Jul; 10():. PubMed ID: 34219653
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand.
    Thomas R; Chansinghakul D; Limkittikul K; Gilbert PB; Hattasingh W; Moodie Z; Shangguan S; Frago C; Dulyachai W; Li SS; Jarman RG; Geretz A; Bouckenooghe A; Sabchareon A; Juraska M; Ehrenberg P; Michael NL; Bailleux F; Bryant C; Gurunathan S
    Hum Immunol; 2022 Jan; 83(1):53-60. PubMed ID: 34635391
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Three-year Efficacy and Safety of Takeda's Dengue Vaccine Candidate (TAK-003).
    Rivera L; Biswal S; Sáez-Llorens X; Reynales H; López-Medina E; Borja-Tabora C; Bravo L; Sirivichayakul C; Kosalaraksa P; Martinez Vargas L; Yu D; Watanaveeradej V; Espinoza F; Dietze R; Fernando L; Wickramasinghe P; Duarte MoreiraJr E; Fernando AD; Gunasekera D; Luz K; Venâncioda Cunha R; Rauscher M; Zent O; Liu M; Hoffman E; LeFevre I; Tricou V; Wallace D; Alera M; Borkowski A
    Clin Infect Dis; 2022 Aug; 75(1):107-117. PubMed ID: 34606595
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and Adults.
    Kallás EG; Cintra MAT; Moreira JA; Patiño EG; Braga PE; Tenório JCV; Infante V; Palacios R; de Lacerda MVG; Batista Pereira D; da Fonseca AJ; Gurgel RQ; Coelho IC; Fontes CJF; Marques ETA; Romero GAS; Teixeira MM; Siqueira AM; Barral AMP; Boaventura VS; Ramos F; Elias Júnior E; Cassio de Moraes J; Covas DT; Kalil J; Precioso AR; Whitehead SS; Esteves-Jaramillo A; Shekar T; Lee JJ; Macey J; Kelner SG; Coller BG; Boulos FC; Nogueira ML
    N Engl J Med; 2024 Feb; 390(5):397-408. PubMed ID: 38294972
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial.
    Tricou V; Sáez-Llorens X; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Saldaña de Suman O; Montenegro N; DeAntonio R; Mazara S; Vargas M; Mendoza D; Rauscher M; Brose M; Lefevre I; Tuboi S; Borkowski A; Wallace D
    Lancet; 2020 May; 395(10234):1434-1443. PubMed ID: 32197107
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials.
    Harenberg A; de Montfort A; Jantet-Blaudez F; Bonaparte M; Boudet F; Saville M; Jackson N; Guy B
    PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004830. PubMed ID: 27459266
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru.
    Lanata CF; Andrade T; Gil AI; Terrones C; Valladolid O; Zambrano B; Saville M; Crevat D
    Vaccine; 2012 Sep; 30(41):5935-41. PubMed ID: 22863660
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA.
    Dayan GH; Thakur M; Boaz M; Johnson C
    Vaccine; 2013 Oct; 31(44):5047-54. PubMed ID: 24021313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.